Purpose: The use of interstitial needles, combined with intracavitary applicators, enables customized dose
 distributions and is beneficial for complex cases, but increases procedure time. Overall, applicator selection is not
 standardized and depends on physician expertise and preference. The purpose of this study is to determine whether
 dose prediction models can guide needle supplementation decision-making for cervical cancer.

Materials and Methods: Intracavitary knowledge-based models for organ-at-risk (OAR) dose estimation were trained and validated for tandem-and-ring/ovoids (T&R/T&O) implants. Models were applied to hybrid cases with 1-3 implanted needles to predict OAR dose without needles. As a reference, 70/67 hybrid T&R/T&O cases were replanned without needles, following a standardized procedure guided by dose predictions. If a replanned dose exceeded the dose objective, the case was categorized as requiring needles. Receiver operating characteristic (ROC) curves of needle classification accuracy were generated. Optimal classification thresholds were determined from the Youden Index.

Results: Needle supplementation reduced dose to OARs. However, 67%/39% of replans for T&R/T&O met all dose
constraints without needles. The ROC for T&R/T&O models had an area-under-curve of 0.89/0.86, proving high
classification accuracy. The optimal threshold of 99%/101% of the dose limit for T&R/T&O resulted in
classification sensitivity and specificity of 78%/86% and 85%/78%.

17 Conclusion: Needle supplementation reduced OAR dose for most cases but was not always required to meet 18 standard dose objectives, particularly for T&R cases. Our knowledge-based dose prediction model accurately 19 identified cases that could have met constraints without needle supplementation, suggesting that such models may be 20 beneficial for applicator selection.

21

- 22 Keywords: knowledge-based; dose prediction; cervix cancer, brachytherapy; needle supplementation
- 23
- 24
- 25
- 26
- 27
- 28
- 29

31 Introduction

32 A brachytherapy boost after external beam radiation (EBRT) is considered to be the standard of care for 33 cervical cancer patients (1, 2). Brachytherapy is often delivered using intracavitary applicators such as tandem-and-34 ring (T&R) or tandem-and-ovoids (T&O) (3). For more complex cases, for example those with large or asymmetric 35 high-risk clinical target volumes (HRCTVs), interstitial needles are often added to better customize the dose 36 distribution, reducing dose to organs-at-risk (OARs), and/or improving HRCTV coverage (4-6). However, using 37 needles increases procedure time and complexity (7). Additionally, the decision to use needles is not standardized 38 and depends on the expertise and preference of the physician. The increased procedural complexity and need for 39 expertise may lead to barriers to brachytherapy implementation, which is problematic given that brachytherapy 40 utilization is diminishing despite its proven benefit (2).

Knowledge-based models for plan quality analysis or automated treatment planning have been extensively
studied in EBRT (8–10), with over a decade of development, many publications and existing commercial solutions.
However, exploration of these methods are comparably rare in brachytherapy (11–13). Knowledge-based models
use prior information from treatment plans to predict dose for new cases based on contours, distances from the
target-to-OARs, and other geometric features (9).

46 Various EBRT studies have proven that the use of knowledge-based models improves plan quality, reduces 47 planning variability and leads to more standardized plans with greater OAR sparing (14-17). Similar to EBRT, 48 knowledge-based models could help to standardize future brachytherapy treatment planning and predicted doses 49 could serve as quality assurance metrics. However, unlike EBRT, brachytherapy plan quality is largely dictated by 50 the applicators and/or needles implanted. There are a variety of different applicators to choose from and strategies 51 for implantation, which leads to large plan quality variations when coupled with variability in treatment planning. 52 Knowledge-based models could play a unique role in brachytherapy, where dose predictions for different treatment 53 types could help to inform the optimal treatment technique.

The purpose of this study is to determine whether knowledge-based models can predict cases where needle supplementation is required to meet dose objectives. To investigate this, existing intracavitary models were applied to hybrid cases treated with additional needles, and estimated OAR doses were used to predict cases that required needle supplementation. Accuracy of classification was verified by replanning all cases without needles, and 58 compared to the current classification in our clinic. Knowledge-based dose estimations could form the basis for
59 more objective, standardized decision-making on necessity of needle usage.

60 Materials and Methods

61 Patient Cohort

62 Cervical cancer patients treated between 2017-2020 with image-guided high-dose-rate brachytherapy with 63 T&O or T&R applicators and 0-3 implanted interstitial needles were included (UCSD IRB #200065C). Treatment 64 planning, applicator reconstruction and contouring were performed based on computed tomography (CT) imaging. 65 Cases implanted with both an intracavitary applicator and needles are referred to as "hybrid" cases. A "case" in this 66 context is defined as a single fraction of a brachytherapy treatment, consisting of 3-5 fractions. Detailed information 67 about the patient cohort is presented in Table 1. Organs and HRCTV (cervix, gross disease and any potential 68 extension) were contoured on the CT. Clinical treatment planning was conducted according to most of the EQD2 69 dose objectives defined by EMBRACE II (18, 19), which include limits (HRCTV D90>85Gy, bladder D_{2cc}<90Gy, 70 rectum D_{2cc}<75Gy and D_{2cc} sigmoid<75Gy) and soft planning aims (recommended but not required, bladder 71 D_{2cc} <80Gy, rectum D_{2cc} <65Gy, and sigmoid D_{2cc} <70Gy). After normalization to point A, plans were optimized to 72 meet objectives and minimize OAR dose. During this process, the overall EQD2 for HRCTV D90 and organ D_{2cc} 73 values were projected using a spreadsheet and then compared to the dose objectives, to ensure that the treatment 74 plan fulfilled all necessary dose criteria. All reported clinical parameters, e.g., D90, V100 and D_{2cc}, were exported 75 directly out of the treatment planning system. All patients received prior EBRT, and the most common EBRT 76 prescription was 45Gy in 25 fractions.

77 Knowledge-Based Dose-Prediction Models

Previously trained and validated dose-prediction models for intracavitary applicators were used. Full details about the algorithm can be found in Yusufaly *et al.* (13), which demonstrates the accuracy of dose-prediction models for cervical cancer patients treated with T&O. Briefly, DVH models are 1D radial models, which predict dose to OARs based on the radial distance from an OAR sub-volume to the HRCTV. OARs are divided into subvolumes based on the boundary distance to the HRCTV contour by overlapping the OAR contour with 2mm shells expanding around the HRCTV. A differential DVH for each OAR shell is extracted from each treatment plan in the training set, and averaged to produce dose kernels as a function of radial distance. For model predictions, OAR contours are discretized in the same manner, and the differential DVH of the considered OAR is calculated from the sum of differential DVH kernels, weighted by the volume of each OAR sub-volume (8, 13, 20). DVHs for new patients can be predicted using HRCTV and OAR contours alone. Additional details about models, are described in the Supplementary Materials. Two different models were trained for T&R or T&O applicators, since these applicators result in significantly different OAR dose (21, 22). The T&R (T&O) model was trained on 75 (80) intracavitary cases and validated on 38 (32) cases (see Table 1 for more details), achieving an approximately 70/30% split between training/validation.

Since OAR D_{2cc} is a common metric used to evaluate brachytherapy plan quality, these metrics were extracted from all DVHs. Unless otherwise stated, D_{2cc} values in results and figures are reported in absolute dose per brachytherapy fraction in Gy. Model performance was quantified using the difference between actual D_{2cc} s obtained from clinical plans and the predicted D_{2cc} s, i.e. ΔD_{2cc} , as well as the standard deviation over these $\sigma_{Model}(\Delta D_{2cc})$, representing model precision. The T&R (T&O) σ_{Model} was 0.66Gy (0.52Gy), 0.39Gy (0.70Gy) and 0.50Gy (0.46Gy) for bladder, rectum and sigmoid, respectively (see Supplementary Figure 4).

Model training, validation and extraction of predicted DVHs were performed using automated scripts in
 MIM (v7.0.1, MIM Software Inc., Cleveland, OH). D_{2cc} calculation and data analysis was performed using
 MATLAB (R2019b, MathWorks, Inc., Natick, MA).

101 Replanning Procedure

102 Seventy (67) hybrid T&R (T&O) cases were replanned without loading the inserted needles to demonstrate 103 the achievable dose using an intracavitary applicator alone (see Supplementary Figure 1, which describes the 104 standardized replanning procedure). This process mimics manual, clinical treatment plan optimization with the 105 addition of dose predictions to guide planning. Patient-specific dose objectives were calculated based on the total 106 number of prescribed fractions and dose as well as the dose received in prior EBRT, to ensure EQD2 objectives 107 were met. First, the clinical treatment plan was reset with standard loading of the intracavitary applicator. After 108 normalizing to point A, the dose distribution was shaped to cover the HRCTV. If the first mandatory aim, HRCTV 109 D90 \ge 85Gy EQD2, was fulfilled then the plan was further tuned to reduce OAR dose, attempting to meet D_{2cc} 110 constraints. The predicted doses were used to guide optimization; however, the aim was to minimize OAR dose, i.e., 111when possible, the plan was further improved until D_{2cc} values were lower than the predicted D_{2cc} values $\pm \sigma_{Model}$. In 112 order to quantitatively replicate the visual evaluation that occurs while planning at our center (i.e., covering the 113 HRCTV target with the prescription isodose) we also attempted to meet a third criteria, $V100 \ge 95\%$ (where 100% 114 corresponds to the prescribed dose per brachytherapy fraction as shown in Table 1), although this was prioritized 115 last. All replans were created by a trained postdoctoral fellow and verified and/or further modified by experienced 116 brachytherapy physicists (DB, DS, KK, XR). All treatment planning was performed in the same brachytherapy 117 planning system (BrachyVision, v15.6, Varian Medical Systems, Inc., Palo Alto, CA). Replanned doses were 118 compared to predicted and actual hybrid dose values using a two-sample Student's t-test (significance level of 0.05).

119 Receiver-Operating-Characteristic Analysis

120 In order to quantify the ability of the models to accurately identify cases that require needles, receiver 121 operating characteristic (ROC) curves were constructed and the area under the curve (AUC) determined. The "true 122 condition" was defined by the replan: any intracavitary plan with an OAR dose exceeding the objective was 123 identified as a case requiring needles. For the model, a threshold was used for needle classification. This threshold 124 was taken as a percentage of the dose objective for an OAR, and was varied from 50% to 200% to reconstruct the 125 ROC plot. Since all dose objectives are based on EQD2 including EBRT, we computed a patient-specific objective 126 for a single brachytherapy fraction by assuming that all brachytherapy fractions received the same dose. Analysis 127 was performed for two different sets of objectives – the dose limits and soft planning aims - since some clinics may 128 use the more conservative aims to determine when to implant needles. True positives were defined as needle cases 129 (any replanned OAR>dose objective) that were correctly identified as such by the model (any predicted OAR 130 dose>threshold). Sensitivity and specificity of the model classification were then calculated for each OAR separately 131 and combined, using the following equations, and positive/negative predictive value (PPV/NPV) were computed.

132 Sensitivity =
$$\frac{\& cases with D2cc, replan \ge dose objective \land D2cc, predict \ge threshold}{\& cases with D2cc, replan \ge dose objective}$$

133 $Specificity = \frac{i cases with D 2 cc, replan < dose objective \land D 2 cc, predict < threshold}{i cases with D 2 cc, replan < dose objective}$

Because the hybrid dataset is biased towards cases requiring needles, an equivalent number of randomly selected intracavitary cases (70 T&R and 67 T&O) were added to the classification analysis. Any plans that did not fulfill HRCTV D90 85-90Gy were rescaled to ensure equivalent coverage to replans. Our current clinical status for needle classification was also determined retrospectively for comparison, which is based on physician experience using knowledge from prior fractions (if any), clinical examination, D90 planning goals based on the number of planned fractions, or imaging. A patient that was actually treated with needles was classified by the physician as needing needles, and vice versa for an intracavitary applicator alone. The optimal threshold for model classification was determined using the Youden index, which maximizes sensitivity and specificity (23). The optimal threshold is defined as the point on the ROC curve that corresponds to the maximal Youden index.

143 Results

144 Comparison of Intracavitary Replans to Actual Clinical Hybrid Plans

145 Organ doses for intracavitary replans are compared to values from clinical hybrid plans in Figure 1. 146 Overall, OAR dose sparing was improved with interstitial needles, especially bladder dose when using T&O. For a 147 single brachytherapy fraction, clinical hybrid implant D_{2cc} for bladder, rectum and sigmoid were, on average, 148 5.23±1.01Gy (5.18±0.84Gy), 2.81±0.93Gy (4.07±0.96Gy), and 4.00±1.04Gy (3.89±1.05Gy), for T&R (T&O) 149 applicators. The replanned OAR doses were higher, on average, with mean T&R (T&O) D_{2cc} of 6.02±2.33Gy 150 (6.53±1.88Gy), 2.95±0.94Gy (4.69±1.86Gy), and 3.91±0.74Gy (4.32±1.61Gy) for bladder, rectum and sigmoid, 151 respectively. Replanned and clinical doses were significantly different for bladder (mean deviation=1.11Gy and 152 p=0.01 for T&R, 1.38Gy and p<0.001 for T&O) and rectum for T&O (mean deviation=0.83Gy, p=0.02).

Using our standardized procedure for replanning, a mean and standard deviation of the HRCTV D90 of 154 $107\pm6\%$ (105 $\pm7\%$) was obtained for all T&R (T&O) cases (see Supplementary Figure 3), where dose is relative to 155 the prescription per brachytherapy fraction. The clinical plans featured greater variation in target coverage, with 156 HRCTV D90 values of 114 $\pm13\%$ (105 $\pm10\%$) for T&R (T&O) applicators. The replans indicated that 67% (39%) of 157 the hybrid T&R (T&O) cases would have met the OAR dose limits and 43% (9%) would have met the softer 158 planning aims without needles.

159 Comparison of Predicted and Replanned Intracavitary Dose

160 The predicted D_{2cc} were, on average for T&R (T&O), 6.02±2.03Gy (6.68±1.16Gy), 3.00±0.86Gy
161 (4.70±0.75Gy), and 4.40±0.79Gy (4.33±0.87Gy) for bladder, rectum and sigmoid respectively. A comparison of
162 predicted and replanned doses is shown in Figure 2 and Supplementary Figure 3. As can be seen in Figure 2 and

163 Table 2, most of the sigmoid and rectum replanned doses fell within precision of the model predictions (i.e. within 164 the grey band), or below. The results for bladder were slightly more variable, particularly for cases exceeding the 165 dose limits, but most cases fell within the diagonal quadrants (indicating that both replan and predicted doses were 166 either greater or less than the dose limits). Besides the sigmoid for the T&R applicator (p < 0.001), the replanned D_{2cc} 167 did not significantly differ from predicted D_{2cc} values. The mean \pm standard deviation of differences between 168 replanned and predicted D_{2cc} (i.e. D_{2cc.replanned}-D_{2cc.predicted}) were 0.00±0.95Gy (-0.15±1.52Gy) for bladder, -169 0.06±0.43Gy (-0.01±1.56Gy) for rectum and -0.49±0.47Gy (-0.01±1.19Gy) for sigmoid for T&R (T&O). As shown 170 in Table 2 and Figure 2, there were very few cases ($\leq 10\%$) for which the replanned dose exceeded the dose limit, 171 while the predicted dose met the limit (top left quadrant of plots in Figure 2). Considering all OARs together, 77% 172 (68%) of T&R (T&O) cases had replanned D_{2cc} values lower than or within the uncertainty of the predictions.

173 Needle Classification Performance Using Dose Limits

174 ROC curves for model needle classification are displayed in Figure 3. The AUC using dose limits as 175 decision criteria for needle supplementation were 0.89 (0.86) for T&R (T&O), indicating good model prediction 176 accuracy. These plots use all organ doses to classify needle cases, while AUC metrics for a single organ are 177 displayed in Table 2. The classification accuracy of our clinic based on the physician's choice of needle usage (red 178 crosses on Figure 4) corresponds to a sensitivity of 72% (73%) and specificity of 56% (67%) for T&R (T&O), 179 which was lower than what was theoretically achieved with the predictions as guidance (Figure 3A and B). The 180 optimal threshold was determined to be 99% of the dose limit for T&R (providing a sensitivity of 78% and 181 specificity of 85%), and 101% of the dose limit for T&O (providing a sensitivity of 86% and specificity of 78%) 182 (black crosses on Figure 4). This corresponded to a PPV and NPV of 61% (74%) and 93% (88%) for T&R (T&O).

183 Needle Classification Performance Using Planning Aims

184 Classification results using planning aims as the decision boundary for needle supplementation were similar. AUC 185 values were 0.88 (0.89) for T&R (T&O). The sensitivity and specificity of the clinical classification were 186 determined to be 66% (60%) and 34% (81%) for T&R (T&O), respectively (Figure 3C and D). The optimal 187 threshold for model classification was 104% of the planning aim for T&R (sensitivity=84% and specificity=81%) and 110% for T&O (sensitivity=79% and specificity=91%). This corresponded to a PPV and NPV of 77% (96%)
and 86% (58%) for T&R (T&O) cases.

190 Discussion

191 This study explores the benefits of knowledge-based models to guide brachytherapy needle 192 supplementation decision-making. Although there are solutions for automating various aspects of brachytherapy 193 treatment planning, such as applicator reconstruction (24–26) and inverse optimization (12, 27), there currently are 194 no tools to guide gynecological applicator choice. Therefore, the addition of interstitial needles is not standardized 195 and relies on the physician's preference and expertise, which is particularly challenging for inexperienced 196 physicians. The proposed model predictions could help physicians make informed decisions based on quantitative 197 metrics.

198 Relative Benefit of Needles vs. Standard Applicators

199 In this series, we found that needles were not always needed to meet the dose objectives. 67% (39%) of the 200 T&R (T&O) hybrid cases could have met the OAR dose limits with an intracavitary applicator alone and 43% (9%) 201 of the T&R (T&O) hybrid cases would have even met the planning aims. However, the use of needles can enable 202 further OAR sparing and/or target dose escalation (28), and sometimes physicians will add needles to achieve either 203 of these goals based on patient and tumor anatomy. The overall objective of treatment planning is to get the best 204 coverage with the lowest OAR doses, and physicians in our clinic often add needles to meet softer planning aims 205 rather than dose limits. Our data showed that supplemental needles resulted in significant dose reductions for 206 bladder (0.78-1.35Gy on average) and rectum (0.43Gy, T&O only). The bladder seemed to benefit the most from 207 needles; for 65% (34%) of T&R (T&O) cases, bladder was the only organ that exceeded the dose limit, indicating 208 that the bladder was the limiting factor for needle requirement. Overall, the hybrid T&O cases had a larger HRCTV 209 volume in comparison to the hybrid T&R cases (see Table 1), which might be linked to the greater percentage of 210 T&O cases requiring needles. Hybrid plans featured a wider range of target coverage than our standardized 211 intracavitary replans, though this may reflect different patient-specific clinical requirements, as opposed to non-212 standardization of planning or applicator differences. The slightly small HRCTV volumes in the hybrid patient group (see Table 1) are likely due to the fact that purely interstitial cases and hybrid cases with more than 3 needleswere excluded.

It is undeniable that needle supplementation can improve dosimetry, but it comes at the cost of increased procedure time and complexity, which is potentially a barrier to institutions that lack brachytherapy expertise or resources. The analysis and tools presented in this study could allow physicians to weigh the relative benefit of needles vs. standard applicators, and to make more informed decisions about needle supplementation that are appropriate for their center.

220 Model Dose-Prediction Accuracy

Dose-prediction models were fully implemented with scripting in MIM, meaning that once images were contoured, OAR dose predictions could be computed within seconds. The use of CT-based planning as opposed to magnetic resonance (MR)-based should not impact results, since the models rely only on the target and organ contours and were trained on cases with a wide range of HRCTV volumes. However, future work will examine model accuracy at institutions that use MR for contouring.

226 This manuscript mainly focuses on the application of knowledge-based models to needle discrimination, 227 but the predicted doses could also be beneficial for patient-specific plan quality control during treatment planning. 228 Model prediction precision ranged from 0.39-0.70Gy for intracavitary validation cases. Although the models were 229 applied to more complex cases, the model performance was still reasonable. Replanned D_{200} values were within the 230 precision of T&R (T&O) model-predictions or lower for 77% (68%) of cases considering all OARs. This result is 231 surprising, given that the model was trained on intracavitary cases, where organ doses rarely exceeded the limits and 232 the anatomy was less challenging. We suspect that prediction accuracy would improve if we added more complex 233 cases to the training set, which would now be possible since we have intracavitary replans for all these patients. The 234 fact that many replanned OAR doses were lower than predicted D_{2cc} - σ_{Model} (see Figure 2) is expected, because the 235 models were produced using variable clinical plans, while replanning was performed using a standardized workflow 236 guided by predictions. This effect has been observed in EBRT studies as well, where using knowledge-based 237 planning significantly reduced OAR dose (29). The current model predictions are most appropriate for quality 238 control of intracavitary treatment plans. Nonetheless, future work will develop separate models for hybrid and interstitial cases in order to provide more accurate D_{2cc} predictions and valuable quality control for more complex cases.

241 Needle Classification Accuracy

242 The ROC analysis and AUCs, ranging between 0.88-0.89 (T&R) and 0.86-0.89 (T&O), demonstrated that 243 knowledge-based models can effectively discriminate between cases that require needles and cases for which an 244 intracavitary applicator is sufficient, with high sensitivity and specificity. The predicted classification was beneficial 245 for needle supplementation guidance when reviewed retrospectively and not considering patient-specific needs. 246 Using the planning aims to guide needle decision-making, which more closely reflects our clinical practice, the 247 current sensitivity of needle selection is 66% (60%) and specificity is 62% (81%) for T&R (T&O), but includes 248 other clinical factors not represented in the model. Dose predictions could improve sensitivity and specificity for 249 T&R (T&O) to 84% (79%) and 81% (91%), respectively, using the optimal threshold of 104% (110%) of planning 250 aims to indicate needle requirement. In practice, this means that one could run the model for a given T&R case and 251 if predicted doses exceeded 104% of the planning aims, needles would be recommended. There would be an 84% 252 chance that a case requiring needles would be accurately identified as such by the model, and an 81% chance that a 253 case would be accurately identified as not requiring needles, if other clinical determinants did not favor needle use. 254 We suspect that the current model predictions (both doses and classification) would be meaningful for any 255 institution using standard T&R or T&O applicators and similar treatment planning criteria. Future work will test the 256 accuracy and applicability of these models on datasets and workflows of independent institutions.

257 Standardized Planning

The standardized planning workflow, driven by knowledge-based dose estimations, was another useful outcome from this work, and could be beneficial to implement in clinical practice. Using the predictions and dose criteria as guidance, a postdoctoral fellow was easily trained to produce clinically acceptable plans in reasonable timeframes (about 10 minutes, not taking catheter digitization and quality assurance into account). Only about 10% of the cases required adjusting after review by experienced brachytherapy physicists. This suggests that guiding treatment planning with predictions could be beneficial for training residents and inexperienced clinicians, and could potentially speed up treatment planning for experienced clinicians. Using patient-specific dose predictions as targets, the planner could push harder on organ dose than they otherwise might have under time constraints, which is usually one limiting factor of plan optimization. This same effect has been reported for EBRT: when only static population-based limits were used to guide planning, high degrees of plan quality variability and excess dose to normal tissues were observed, while when patient-specific achievable dose limits were provided, variability and normal tissue doses were substantially reduced (30, 31). Standardized planning, guided by dose predictions, could help physicians and physicists create optimal treatment plans for patients and standardize plan quality.

271 Proposed Clinical Workflow Using Needle Supplementation Guidance

272 Models are most accurate for same-day predictions, and thus would be very beneficial for centers with 273 image-guided brachytherapy suites (see Figure 4A for proposed workflow in clinical implementation). In this case, 274 an intracavitary applicator should be implanted for each fraction, and after imaging and contouring, the models 275 should be used to predict if needles should be added. Adding needles and re-imaging after initial imaging may only 276 be feasible at a minority of centers (32), so we also propose the following alternative workflow (see Figure 4B). For 277 the first fraction, prior knowledge from examination and imaging should be used to decide if needle supplementation 278 is necessary, prioritizing the use of purely intracavitary applicators. If the patient anatomy includes specific features, 279 such as irregular tumor topography, tumor size>4cm, bulky parametria disease or posterior bulky disease, needles 280 should be implanted. After contouring on imaging, model-based predicted organ doses should be obtained. If any 281 predicted organ dose exceeds 99% (101%) of the dose limit for T&R (T&O), the next fraction should be 282 supplemented with needles. Physicians that prefer to implant needles to meet the planning aims would instead 283 implant needles if any predicted OAR dose exceeded 104% (T&R) or 110% (T&O) of the planning aim. Although 284 actual organ doses are available after treatment plan optimization, we still recommend using model predictions to 285 guide decision-making in case treatment planning was suboptimal. This procedure should be repeated for each of the 286 following fractions, such that the applicator decision is guided by dose predictions of the previous fraction. 287 Physicians who are more comfortable with needle usage and prefer to err on the side of caution could choose to 288 implant needles more often for the first fraction; however, the following workflow determining needle requirement 289 for the following fraction could still apply. Finally, for any fraction treated without needles, we would recommend 290 aiming for the predicted organ doses (minus model precision) when treatment planning, and comparing the final 291 organ doses to predicted values as a means of quality control.

292 Using the models provides the following benefits to clinicians over current clinical practice. For one, 293 current treatment planning is performed under time pressure, and thus clinicians may not be able to easily determine 294 the optimal dose for a patient in the allotted time. For purely intracavitary implants, a clinician may believe that 295 needles are needed for the next fraction, while more optimal treatment planning could have met constraints. The 296 models provide reasonable estimates of achievable OAR dose with intracavitary applicators, which could speed up 297 the planning process, provide additional assurance that the treatment plan is optimal and confirmation as to whether 298 needles will be needed in future fractions. A physician may choose to insert needles for one fraction, but without 299 replanning the case without needles, they may not know for sure whether needles were actually necessary to meet 300 dose constraints. Our own data shows that needles were over-used, and thus there is room for improvement even 301 within an experienced, busy brachytherapy clinic. The models can provide additional guidance on what to do for the 302 next fraction on these borderline cases.

303 Limitations and Future Work

304 The models were trained on clinical treatment plans, but brachytherapy plans are not homogenous and a 305 decent amount of variation between plans, individualized for the needs of each patient, is to be expected. This means 306 some variability is incorporated into the models; however, we expect that much of this variation averaged out over 307 the large patient cohort. The models are simple and make assumptions about dose conformality to the HRCTV, 308 which do not perfectly hold for the standard pear-shaped distributions of cervical brachytherapy dose. The models 309 also are less accurate when the tandem is not centered on the HRCTV, which necessitated an additional correction 310 for HRCTV asymmetry to improve bladder dose predictions (see Supplementary Materials). Despite these 311 limitations, the models were accurate for needle discrimination in their current form. Future work will explore 3D 312 dose prediction, which can account for greater complexities in anatomy and applicator geometry.

One limiting factor is that dose-prediction models assume standard situations and do not account for any dose received in previous fractions or other individual patient needs (such as additional dose to the vagina). We recognize physicians consider additional clinical data and the full patient history during treatment planning. For instance, physicians may opt to increase target coverage, and this is not reflected in either the replanning or predicted doses. These factors influence of the clinical classification and retrospective analysis of sensitivity and specificity. To provide a more fair comparison, a prospective evaluation of physician classification based solely on whether OARs are anticipated to meet dose objectives (i.e. without HRCTV dose escalation) is needed. This will be explored in future work. However, the models indicate what kind of dose is achievable if target coverage of D90 85-90Gy is met, and whether needles are required to meet dose objectives. Physicians could use this information to guide decision-making for a given case alongside other characteristics they value. If the models are employed at the first fraction, inter-fraction variability may be reduced, and the need to compensate for non-ideal dose from prior fractions could be alleviated.

325 The addition of the HRCTV V100 criteria to replanning objectives meant that HRCTV D90 could take on a 326 range from 85 to 90 Gy EQD2. As a result, patients with different prescriptions could have slightly different target 327 coverage, which could impact both organ D_{2cc} and needle classification in replans. In order to assess whether 328 prescription was influencing results, we compared the following parameters between patients treated with different 329 fractionation schemes using a Kruskal-Wallis test with a Bonferroni correction: D_{2cc,replanned} - dose limit and 330 $D_{2cc,replanned} - D_{2cc,predicted}$. A chi-squared test of independence was used to determine whether fractionation scheme was 331 related to the following binary outcomes: D_{2cc,replanned} greater or less than the dose limit and model classification 332 accurate or inaccurate. All tests were insignificant, demonstrating that the variable prescriptions within our patient 333 cohort were not systematically impacting any of our key results.

334 One drawback of the proposed algorithm is that the necessity of needle supplementation is evaluated after 335 implantation of the applicator and imaging. This means that the model cannot guide needle decision-making for the 336 first fraction, and so the decision purely depends on the physician expertise, preference and fractionation schema. 337 However, predictions could still be used to inform needle implantation of subsequent fractions. In addition, our 338 current models do not provide guidance on the number and location of needles required to meet dose criteria. 339 Another limitation is that sensitivity and specificity of model classification was not tested on an independent dataset 340 and this may bias our results towards better model classification. Future work will examine the utility of this 341 decision-support tool and the standardized planning workflow in clinical practice.

342 Conclusion

The benefit of knowledge-based intracavitary models to support the decision to use needles was demonstrated. Standardized replanning of hybrid cases without needles confirmed model prediction accuracy. ROC curves and AUCs demonstrated the discrimination accuracy of the tool, which featured much higher sensitivity and specificity than our current clinical process for needle classification. The analysis showed that needles are sometimes avoidable with little detriment to the patient, but could reduce organ dose, especially for the bladder. In summary, standardized planning driven by knowledge-based dose predictions could influence needle usage, serve as guidelines for physicians and decrease variations between treatment plans.

350 Disclosure

351 Dr. Meyers, Moore and Mayadev report grants from Padres Pedal the Cause during the conduct of the study. Dr. 352 Moore acknowledges funding support from AHRQ (R01 HS025440-01), has a patent Developing Predictive Dose-353 Volume Relationships for a Radiotherapy Treatment licensed to Varian Medical Systems, and a patent for 354 knowledge-based prediction of three-dimensional dose distributions pending. Outside the submitted work, Dr. 355 Moore, Ray, Brown and Scanderbeg acknowledge research funding, travel support, and honoraria from Varian 356 Medical Systems; Dr. Scanderbeg reports personal research funding from Merit Medical; Dr. Mayadev reports 357 personal fees from AstraZeneca, grants from NRG Oncology and GOG Foundation, and personal fees from Varian 358 Medical Systems; Dr. Simon reports personal fees from Courage Health, Inc.





Figure 1. D_{2cc} values established by replanning the hybrid cases to purely intracavitary treatment plans (i.e. organ dose without needles), compared to actual D_{2cc} values obtained from clinical hybrid plans (i.e. organ dose with needles). Replans required HRCTV D90 to fall between 85-90Gy EQD2. The dashed black line denotes the one-to-one line of replanned and actual dose. Values below the dashed line show cases where replanning without needles improved D_{2cc} values. Values above the dashed line show cases where the usage of needles improved the D_{2cc} values; $x = D_{2cc, replan} >$ dose limit; $o = D_{2cc, actual} >$ dose limit.



369 Figure 2. Predicted deviations from dose limits compared to those of the replans, where 370 $\delta D_{2cc} = D_{2cc}$ -patient and organ-specific dose limit. Predictions were obtained from 371 knowledge-based intracavitary models, while replan values were established by re-planning 372 the hybrid cases without needles, requiring a HRCTV D90 of 85-90Gy EQD2. The dashed 373 black line denotes the one-to-one line of replanned and predicted doses, and the model 374 precision is displayed as the grey band. The four quadrants are labeled as if a threshold of 100% of the dose limits was used for model classification (although this threshold was 375 376 varied in the ROC analysis). Cases located in the bottom left and top right quadrant were 377 correctly predicted as not needing needles (true negatives) or needing needle 378 supplementation (true positives). Cases in the top left quadrant were falsely classified that 379 needles are unnecessary (false negatives), while cases in the bottom right quadrant were 380 predicted to require needles but could have been met the dose limits with the standard 381 applicator alone (false positives).





Figure 3. ROC curve and corresponding area-under-curve (AUC) for both applicators, considering all organ doses. Replanned D_{2cc} values are used as true condition (where any case with an organ dose exceeding the dose limit (A and B) or the planning aim (C and D) is considered to be a true needle case) and compared to the predicted D_{2cc} values for varying thresholds. The red cross indicates our current clinically achieved values of specificity and sensitivity classified by the physician; --- boundary marking the goodness of the prediction being better than randomness.

391



392

393 Figure 4. Suggested clinical workflows using the dose predictions to guide needle 394 supplementation and treatment planning. (A) proposed workflow for centers where adding 395 needles after imaging and subsequent re-imaging are feasible, such as those with image-396 guided brachytherapy suites. If this is not feasible, (B) shows an alternative workflow where 397 predictions are used to guide decision-making for the subsequent fraction. *Optimal 398 threshold defined by the maximal Youden index, i.e. 99% (101%) of dose limit or 104% 399 (110%) of planning aim for T&R (T&O), where use of dose limits or planning aims is based on 400 physician preference.

402 **Table 1.** Summary of patient specifications of evaluated hybrid cases and intracavitary model data; IC 403 = intracavitary; IS = interstitial; T&R = tandem and ring applicator; T&O = tandem and ovoids 404 applicator; T&RN = hybrid tandem and ring applicator with needles; T&ON = hybrid tandem and 405 ovoids applicator with needles; HRCTV = high-risk clinical target volume.

Туре	Parameter	Applicator	Specification	Value
Intracavitary	Number of included patients	T&R	Total	47
		T&O	Total	36
	Number of included fractions	T&R	Training cases	75
			Validation cases	38
		T&O	Training cases	80
			Validation cases	32
	HRCTV volume [cc]	T&R	Median (Range)	18.00 (4.9 - 40.2)
		T&O	Median (Range) Median (Range) 3 x 7.0Gy 3 x 7.5Gy 3 x 8.0Gy 3 x 8.5Gy 4 x 5.5Gy 4 x 7.0Gy 4 x 7.5Gy 5 x 6.0Gy	17.90.49 (7.7 - 65.7)
	Number of patients receiving each	T&R	3 x 7.0Gy	2
	prescription (total number		3 x 7.5Gy	2
	fractions x dose per fraction)		3 x 8.0Gy	12
			3 x 8.5Gy	1
			4 x 5.5Gy	1
			4 x 7.0Gy	29
				1
				3
		T&O	3 x 8.0Gy	3
			4 x 7.0Gy	15
			4 x 6.0Gy	1
			5 x 5.5Gy	4
			5 x 6.0Gy	12
			Median (Range) 3 x 7.0Gy 3 x 7.5Gy 3 x 8.0Gy 3 x 8.5Gy 4 x 5.5Gy 4 x 7.0Gy 4 x 7.5Gy 5 x 6.0Gy 3 x 8.0Gy 4 x 7.0Gy 4 x 7.0Gy 5 x 6.0Gy 5 x 5.5Gy	1
	Number of patients with each	T&R		22
	tumor stage	ients T&R Total T&O Total T&O Total T&O Training cases Validation cases T&O Training cases Validation cases T&O Median (Range) T&R Median (Range) T&O TO	19	
				5
	IV	IV	1	
		T&O		13
				20
				3
			IV	0
Hybrid (IC /IS)	Number of included patients	T&RN	Total	32
		T&ON	Total	28

Number of replanned fractions	T&RN	Total	70
	T&ON	Total	67
HRCTV volume [cc]	T&RN	Median (Range)	24.6 (9.7 - 73.4)
	T&ON	Median (Range)	30.60 (12.7 - 97.6)
 Number of patients receiving each	T&RN	3 x 7.0Gy	1
prescription (total number		3 x 8.0Gy	9
fractions x dose per fraction)		4 x 7.0Gy	21
		5 x 6.0Gy	1
	T&ON	3 x 7.0Gy	1
		3 x 8.0Gy	4
		4 x 7.0Gy	19
		4 x 7.5Gy	2*
		5 x 5.0Gy	2
Number of patients with each	T&RN	Ι	10
tumor stage		II	15
		III	7
		IV	0
	T&ON	Ι	9
		II	10
		III	7
		IV	0

406 *for one patient, one of the fractions was treated with 5Gy

Table 2. Results of the comparison of the predicted D_{2cc} values to the replanned D_{2cc} values, where the replanned value represents the true result. Percentage of total amount of cases is shown where the argument stated as parameter is met. OAR = organs-at-risk; T&R = tandem and ring applicator; T&O = tandem and ovoids applicator; AUC = area under curve; σ_{Model} = model-prediction precision

Damamakan	O A D	Result		
Parameter	OAR	T&R	T&O	
	Bladder	71%	55%	
Banlannad D (OAD limit	Rectum	96%	70%	
Replanned $D_{2cc} < OAR$ limit	Sigmoid	91%	78%	
	All OARs	67%	39%	
	Bladder	40%	6%	
Replanned $D_{2cc} \leq actual$	Rectum	36%	28%	
clinical D _{2cc}	Sigmoid	49%	34%	
	All OARs	21%	1%	
	Bladder	83%	79%	
Replanned D _{2cc} < predicted	Rectum	87%	90%	
$D_{2cc} + \sigma_{Model}$	Sigmoid	97%	82%	
	All OARs	77%	68%	
D mediation mat OAD	Bladder	10 %	6%	
D _{2cc} prediction met OAR	Rectum	4%	7%	
limits, but replanned D_{2cc} > OAR limit	Sigmoid	3%	6%	
UAK IIIIII	All OARs	9%	-	
D mediation > OAD	Bladder	4%	18%	
D_{2cc} prediction > OAR	Rectum	3%	13%	
limits, but replanned $D_{2cc} \leq OAR$ limit	Sigmoid	9%	10%	
OAR IIIIII	All OARs	11%	19%	
AUC of hubrid	Bladder	0.82	0.88	
AUC of hybrid +	Rectum	0.97	0.90	
intracavitary cases	Sigmoid	0.92	0.86	
considering dose limit	All OARs	0.89	0.86	
AUC of hubrid	Bladder	0.83	0.86	
AUC of hybrid +	Rectum	0.92	0.93	
intracavitary cases	Sigmoid	0.92	0.86	
considering planning aims	All OARs	0.88	0.90	

414 References

- 415 [1] Gill BS, Lin JF, Krivak TC, et al. National Cancer Data Base Analysis of Radiation Therapy Consolidation
 416 Modality for Cervical Cancer: The Impact of New Technological Advancements. *Int J Radiat Oncol* 2014;
 417 90: 1083–1090.
- 418 [2] Han K, Milosevic M, Fyles A, et al. Trends in the Utilization of Brachytherapy in Cervical Cancer in the United States. *Int J Radiat Oncol Biol Phys* 2013; 87: 111–119.
- 420 [3] Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations
 421 Committee, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. *Brachytherapy* 2012; 11: 33–46.
- 423 [4] Lombe D, Crook J, Bachand F, et al. The addition of interstitial needles to intracavitary applicators in the treatment of locally advanced cervical cancer: Why is this important and how to implement in low- and middle-income countries? *Brachytherapy* 2020; 19: 316–322.
- 426 [5] Walter F, Maihöfer C, Schüttrumpf L, et al. Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results. *Brachytherapy* 2018; 17: 775–781.
- [6] Nomden CN, de Leeuw AAC, Moerland MA, et al. Clinical Use of the Utrecht Applicator for Combined Intracavitary/Interstitial Brachytherapy Treatment in Locally Advanced Cervical Cancer. *Int J Radiat Oncol* 2012; 82: 1424–1430.
- 432 [7] Dimopoulos JCA, Kirisits C, Petric P, et al. The Vienna applicator for combined intracavitary and interstitial
 433 brachytherapy of cervical cancer: Clinical feasibility and preliminary results. *Int J Radiat Oncol* 2006; 66:
 434 83–90.
- 435 [8] Appenzoller LM, Michalski JM, Thorstad WL, et al. Predicting dose-volume histograms for organs-at-risk in IMRT planning. *Med Phys* 2012; 39: 7446–7461.
- 437 [9] Ge Y, Wu QJ. Knowledge-based planning for intensity-modulated radiation therapy: A review of data-438 driven approaches. *Med Phys* 2019; 46: 2760–2775.
- 439 [10] Shiraishi S, Moore KL. Knowledge-based prediction of three-dimensional dose distributions for external beam radiotherapy. *Med Phys* 2016; 43: 378–387.
- [11] Nicolae A, Morton G, Chung H, et al. Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy. *Int J Radiat Oncol* 2017; 97: 822–829.
- 443 [12] Shen C, Gonzalez Y, Klages P, et al. Intelligent inverse treatment planning via deep reinforcement learning, a proof-of-principle study in high dose-rate brachytherapy for cervical cancer. *Phys Med Biol* 2019; 64: 115013.
- 446 [13] Yusufaly TI, Kallis K, Simon A, et al. A knowledge-based organ dose prediction tool for brachytherapy
 447 treatment planning of patients with cervical cancer. *Brachytherapy* 2020; 19: 624–634.
- 448 [14] Cornell M, Kaderka R, Hild SJ, et al. Noninferiority Study of Automated Knowledge-Based Planning
 449 Versus Human-Driven Optimization Across Multiple Disease Sites. *Int J Radiat Oncol Biol Phys* 2020; 106: 430–439.

- Tol JP, Dahele M, Gregoire V, et al. Analysis of EORTC-1219-DAHANCA-29 trial plans demonstrates the potential of knowledge-based planning to provide patient-specific treatment plan quality assurance.
 Radiother Oncol 2019; 130: 75–81.
- 454 [16] Younge KC, Marsh RB, Owen D, et al. Improving Quality and Consistency in NRG Oncology Radiation
 455 Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning. *Int J Radiat Oncol Biol Phys* 2018; 100: 1067–1074.
- 457 [17] Giaddui T, Geng H, Chen Q, et al. Offline Quality Assurance for Intensity Modulated Radiation Therapy
 458 Treatment Plans for NRG-HN001 Head and Neck Clinical Trial Using Knowledge-Based Planning. Adv
 459 Radiat Oncol 2020; 5: 1342–1349.
- 460 [18] Pötter R, Haie-Meder C, Limbergen EV, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 2006; 78: 67–77.
- 464 [19] Chino J, Annunziata CM, Beriwal S, et al. Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Pract Radiat Oncol* 2020; 10: 220–234.
- 466 [20] Covele BM, Puri KS, Kallis K, et al. ORBIT-RT: A Real-Time, Open Platform for Knowledge-Based
 467 Quality Control of Radiotherapy Treatment Planning. *JCO Clin Cancer Inform* 2021; 134–142.
- 468 [21] Biltekin F, Gultekin M, Yilmaz MT, et al. Dosimetric comparison of two different applicators and rectal retraction methods used in inverse optimization-based intracavitary brachytherapy for cervical cancer. J Contemp Brachytherapy 2020; 12: 35–43.
- 471 [22] Serban M, Kirisits C, de Leeuw A, et al. Ring Versus Ovoids and Intracavitary Versus Intracavitary472 Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study. Int J
 473 Radiat Oncol Biol Phys 2020; 106: 1052–1062.
- 474 [23] Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. *Biom J Biom Z* 2005; 47: 458–472.
- 476 [24] Damato AL, Viswanathan AN, Don SM, et al. A system to use electromagnetic tracking for the quality assurance of brachytherapy catheter digitization. *Med Phys* 2014; 41: 101702.
- 478 [25] Jung H, Shen C, Gonzalez Y, et al. Deep-learning assisted automatic digitization of interstitial needles in 3D CT image based high dose-rate brachytherapy of gynecological cancer. *Phys Med Biol* 2019; 64: 215003.
- 480 [26] Zhou Y, Klages P, Tan J, et al. Automated high-dose rate brachytherapy treatment planning for a single-channel vaginal cylinder applicator. *Phys Med Biol* 2017; 62: 4361–4374.
- 482 [27] Cv G, Kp A, R M, et al. Real-time inverse high-dose-rate brachytherapy planning with catheter optimization by compressed sensing-inspired optimization strategies. *Phys Med Biol* 2016; 61: 5956–5972.
- 484 [28] Fokdal L, Sturdza A, Mazeron R, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. *Radiother Oncol* 2016; 120: 434–440.
- 487 [29] Kaderka R, Mundt RC, Li N, et al. Automated Closed- and Open-Loop Validation of Knowledge-Based
 488 Planning Routines Across Multiple Disease Sites. *Pract Radiat Oncol* 2019; 9: 257–265.

- 489 [30] Moore KL, Schmidt R, Moiseenko V, et al. Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126. *Int J Radiat Oncol* 2015; 92: 228–235.
- 491 [31] Nelms BE, Chan MF, Jarry G, et al. Evaluating IMRT and VMAT dose accuracy: Practical examples of failure to detect systematic errors when applying a commonly used metric and action levels. *Med Phys* 2013; 40: 111722.
- 494 [32] Tambas M, Tavli B, Bilici N, et al. Computed Tomography-Guided Optimization of Needle Insertion for
 495 Combined Intracavitary/Interstitial Brachytherapy With Utrecht Applicator in Locally Advanced Cervical
 496 Cancer. *Pract Radiat Oncol.* Epub ahead of print 5 February 2021. DOI: 10.1016/j.prro.2021.01.008.